© 2026 Sinochem Nanjing Corporation,
All Right Reserved
The story of 7-Amino-3-Desacetoxy-3-Cephem-4-Carboxylic Acid traces back to the search for new antibiotics in the aftermath of penicillin's discovery. This molecule, known by researchers as 7-ADCA, came out of cephalosporin antibiotic development in the 1960s. Researchers scavenged for substances that could resist beta-lactamase enzymes. The focus shifted from penicillins to cephalosporins, building a foundation for broad-spectrum antibiotics. By the 1970s, chemical techniques improved, making it easier to isolate and manipulate cephalosporin intermediates. This progress opened the way for more targeted drug design, and 7-ADCA became a backbone for new-generation antibiotics.
7-ADCA plays a key role as a core building block in the manufacturing of semi-synthetic cephalosporins. The pharmaceutical world relies on this intermediate to produce active drugs that tackle everything from respiratory infections to skin wounds. Chemical companies synthesize this molecule for large-scale use in creating cephalexin and cefadroxil—themselves critical in clinical settings. When it lands in a production plant, 7-ADCA isn’t the end goal. It’s a starting point for many chemical reactions that turn it into tailored medicines, fitting into the cephalosporin family tree.
This compound presents itself as a white to pale yellow, crystalline or powdery substance. Its melting point hovers around 175-185°C, a region that speaks to its stability in industrial syntheses. Water solubility varies by salt form, but it remains moderately soluble, making it workable for both chemical and pharmaceutical processes. Unlike some unstable intermediates, 7-ADCA maintains solid shelf stability under dry, cool storage. Chemically, it holds a beta-lactam ring fused to a dihydrothiazine structure, a signature scaffold for the cephalosporins. On the molecular scale, the exact composition reads C8H8N2O3S, and a keen eye can pick out its functional groups that open doors to downstream synthesis.
The pharmaceutical industry pays close attention to 7-ADCA’s purity. Impurity levels must often stay below 1.0% for contaminants and under 0.5% for related substances, a standard set by global pharmacopeias. A typical batch will carry an assay result above 98%. Labels will clearly mark batch numbers, manufacturer name, and recommended storage instructions: keep dry, protect from light, and avoid extreme temperatures. For bulk deliveries, drums and polyethylene-lined containers protect the product from moisture and degradation. Regulations in Europe, the US, and Asia require conformity with Good Manufacturing Practices (GMP) and full traceability of each lot right from synthesis to shipping.
Manufacturers begin with a cephalosporin C substrate extracted from Acremonium chrysogenum, a fungus cultivated under controlled fermentation. Chemical engineers treat cephalosporin C with D-amino acid oxidase, catalyzing the removal of certain side chains. This produces the parent nucleus of 7-ADCA. Crystallization and filtration steps refine it further. Industrial batches scale this process using bioreactors, leveraging advances in enzyme technology to reduce byproducts and environmental burden. Problems sometimes arise in removing impurities, but robust chromatography and aqueous workups do the trick.
The real chemistry happens when 7-ADCA takes part in acylation. Its amino group reacts readily with various acid chlorides, setting off synthesis of different cephalosporin antibiotics. Seasonal shifts in raw material quality often force production tweaks. The chemical structure tolerates substituent modifications around the beta-lactam ring, making it an adaptable intermediate in medicinal chemistry. Chloroacetylation, amidation, and esterification serve as core modifications that shape the antibacterial spectrum and pharmacological behavior of the final drug.
Research and production notes often substitute 7-ADCA for other names. Common terms include 7-Aminocephalosporanic acid and 7-Aminodesacetoxycephalosporanic acid. Some companies reference it by its short codes—ADCA or 7-ACA—though chemists distinguish carefully between similar analogs. Regulatory documents require precise identification to avoid confusion with 7-ACA (7-aminocephalosporanic acid), which has slightly different properties and end uses.
Production labs treat the compound with respect. Direct contact can irritate skin or eyes, and inhalation of fine powders poses respiratory hazards, especially where automation isn’t perfect. Production teams use disposable gloves, goggles, and dust masks as standard procedure on the shop floor. Material Safety Data Sheets specify how to clean up accidental spills—usually wet mopping to keep dust down. Since the compound is often made in bulk, European REACH and US OSHA rules both control worker exposure and disposal practices. Medical researchers continue investigating if trace exposures can trigger allergies in sensitive individuals, especially those with a history of beta-lactam reactivity.
Doctors have depended on derivatives of 7-ADCA for decades to treat infections unresponsive to older antibiotics. Drug manufacturers depend on it to produce oral and injectable cephalosporins for a wide range of illnesses: pneumonia, urinary tract infections, cellulitis, and more. Outside the clinic, research labs use 7-ADCA to study new antibacterial agents. It remains a standard intermediate in pharmaceutical production, owing to its reliable input to the cephalosporin chemical lineage. Hospitals worldwide bank on these drugs to fight resistant bacteria, which brings this intermediate into indirect contact with millions of lives each year.
Industry and academia have poured resources into optimizing how 7-ADCA is made and used. Enzyme engineering brought down the cost of synthesis. In some labs, teams have used directed evolution techniques to improve the D-amino acid oxidase used in its prep. More recently, machine learning tools analyze the byproducts that come off certain reaction steps, guiding refinements in process chemistry. Collaborative projects with universities allow faster discovery of new cephalosporin analogs by plugging different side chains onto the 7-ADCA backbone. These collaborations keep the science moving forward, bringing new possibilities year after year.
Toxicological studies show that 7-ADCA itself does not cause acute toxicity at ordinary exposure levels in manufacturing. Most of the concern lies in rare allergic responses and the potential for contamination with less-characterized byproducts. Chronic exposure data remain limited, but standard protective measures in the workplace appear to keep health risks very low. Animal studies confirm that the molecule in its intermediate form does not trigger the same side effects as active cephalosporin antibiotics, though direct injection is avoided outside controlled environments. As with most intermediates, regulatory bodies demand ongoing research into mutagenicity and carcinogenicity, especially as synthesis methods evolve.
The future for 7-ADCA looks bright but challenging. On one hand, scientists anticipate new cephalosporin generations, using this backbone to outsmart resistant bacteria. With antibiotic resistance ticking upwards worldwide, the medical field cannot afford to stand still. Advances in biocatalysis could cut down on waste, improve yield and maybe even lower costs for health systems. Sustainability pressures urge producers to keep refining how they make and recover chemicals in each batch. As personalized medicine gains ground, the flexibility of 7-ADCA’s chemistry will likely fuel the creation of antibiotics tailored to stubborn or rare infections, pushing the boundaries of what this old intermediate can do in a new era.
People often talk about miracle drugs, but most don’t think about life before antibiotics. Bacterial infections killed healthy people without mercy. Today, picking up a prescription at the pharmacy feels routine, yet the process of making those pills relies on a tight web of chemistry and research.
Let’s dig into one building block in that web: 7-Amino-3-Desacetoxy-3-Cephem-4-Carboxylic Acid. The name winds around the tongue, but the science behind it shapes entire generations of antibiotics. Drug makers use it as a core ingredient to create cephem antibiotics, which belong to the cephalosporin family. These medicines often come into play when older antibiotics like penicillin can’t stop serious bacteria.
7-Amino-3-Desacetoxy-3-Cephem-4-Carboxylic Acid, called 7-ADCA by many in the field, acts as a starting molecule for cephalosporin antibiotics. It has a distinct, ring-shaped structure that gives it solid antibacterial properties. Chemists take this core and swap out side chains, shaping the activity of the final drug. Through small changes, they can create antibiotics to outsmart bacteria that keep changing their defenses.
What does this mean for personal health? The cephalosporin group covers some of the most prescribed antibiotics in hospitals and clinics. Doctors use them for everything from skin infections to pneumonia to cases when people can’t tolerate penicillin. The benefits reach deeper than treating coughs. Stronger cephalosporins can handle tough infections, including those picked up during surgery.
In my experience working at a pharmacy, I have seen more patients each year picking up complicated antibiotics. Bacteria learn fast, and resistance grows every time someone uses antibiotics the wrong way. Hospitals keep looking for new solutions, and that’s where chemical intermediates like 7-ADCA carry real weight. They allow drug companies to test new versions and tweak drug properties, so bacteria have a harder time developing resistance.
There’s a race happening behind the scenes: scientists on one side, bacteria on the other. Chemists need solid building blocks. Without 7-ADCA, the toolkit shrinks. A shortage or supply chain disruption for these compounds can slow the introduction of new antibiotics. According to the World Health Organization, resistant infections cause hundreds of thousands of deaths worldwide. That makes steady access to these ingredients a real public health concern.
Pharmaceutical production relies on global manufacturing. Many of these antibiotic ingredients get made in specialized facilities across Asia and Europe. If just one factory goes down, or countries tighten export rules, drug shortages can follow. Seeing this risk up close, I’ve come to appreciate calls for more domestic investment and tighter regulation of overseas suppliers.
Greater transparency across the antibiotic supply chain helps everyone: patients, healthcare workers, and policymakers. Funding public research into next-generation antibiotics, streamlining approval for manufacturing plants, and cracking down on overuse all matter. If these steps come together, they can keep important ingredients like 7-ADCA flowing and help medical teams keep tough infections in check.
Walking through the details of antibiotic science, few molecules grab the spotlight quite like 7-Amino-3-Desacetoxy-3-Cephem-4-Carboxylic Acid. This compound, often shortened to 7-ADCA, acts as a core structure for many cephalosporin antibiotics. Researchers and pharmaceutical manufacturers rely on it as a starting point for changing, improving, and fine-tuning new treatments. The molecular formula of 7-ADCA is C8H9N3O3S, bringing together carbon, hydrogen, nitrogen, oxygen, and sulfur in a very specific—and powerful—arrangement.
The chemical structure of 7-ADCA tells the story of its function. At its heart stands the cephem nucleus, a four-membered β-lactam ring fused to a six-membered dihydrothiazine ring. Having worked in laboratories and seen how small structural changes drive enormous differences in antibiotic properties, I can say the precision here isn’t just chemistry for chemistry’s sake. Small tweaks mean bacteria could become sensitive or resistant overnight. The specific “7-amino” position unlocks further modification for drug development. The missing acetoxy group at position 3 distinguishes this molecule from other cephalosporins, making it more flexible for chemical tailoring.
Academic textbooks and articles might swirl with complex diagrams. Out in the field, experts, pharmacists, and chemists pay attention to 7-ADCA because of its potential. This molecule forms the backbone for a range of life-saving medicines. Since the β-lactam ring is vulnerable to β-lactamase enzymes produced by resistant bacteria, teams constantly explore how changes to this structure might keep antibiotics active in the fight. At a practical level, the carboxylic acid group at position 4 adds solubility, making the compounds it spawns more bioavailable. The amino group at position 7 sets the stage for a wide array of substitutions—each resulting in a drug with unique properties against infections.
Reports over the past decade sound alarm bells over the rise of antibiotic resistance. In real-world clinics, outcomes depend on having new weapons ready when common infections turn deadly. With a solid understanding of structures like 7-ADCA, researchers keep their edge and respond quickly to emerging threats. Tapping into this molecule, firms can introduce side chains that resist bacterial enzymes or fine-tune pharmacokinetics for better patient outcomes. Investing in better synthetic routes for 7-ADCA isn’t just a chemistry challenge—it's a matter of global health.
I’ve seen firsthand how collaborations between chemists, biologists, and industry partners turn basic building blocks into frontline medicines. Keeping up funding for foundational research, supporting collaborative manufacturing, and ensuring education about basic structures makes all the difference. As more researchers train their sights on molecules like 7-ADCA, I hope to see a new generation of antibiotics take shape. In the end, lives depend on how well the next round of medicines stand up to evolving challenges—and 7-ADCA remains a starting point with proven promise.
Looking for 7-Amino-3-Desacetoxy-3-Cephem-4-Carboxylic Acid, also called 7-ADCA, reveals plenty about the bigger picture of global pharmaceuticals. As a key building block for making β-lactam antibiotics, 7-ADCA pulls at the strings of both science and regulation. From my own experience speaking with drug makers and chemistry suppliers, serious hurdles line the path to a purchase.
Let’s look at price first. Most producers spread across China, a few in India, and some in Europe, treat this compound as a specialty chemical. They rarely list it on typical public-facing e-commerce platforms. Interested parties usually start with an inquiry and end up negotiating minimum order quantities. Prices shift depending on batch size, final purity, and proof of legitimate end use. In 2023, European suppliers quoted between $450 and $650 per kilogram in bulk packaging. Smaller labs paid a premium, and the supply chain kept tightening. Recent regulatory crackdowns on antibiotic precursors caused longer lead times and higher screening.
The story behind 7-ADCA’s availability always loops back to health and safety. This molecule forms the core for widely used antibiotics like cefalexin and cefadroxil. As bacteria evolve, governments worry about resistance, so they guard foundational chemicals. Every purchase triggers a check—buyers must show licenses, import permits, and secure storage plans. No surprise, since black-market production and environmental dumping both carry real risks. In 2022, Chinese regulators intercepted unauthorized shipments to Southeast Asia, underlining the strict oversight.
Unlike many common reagents, 7-ADCA sometimes pops up on watch lists in the U.S. and EU. That means customs agencies look out for unusual imports, blocking unknown sources and banning anonymous sellers. Small research labs often get stuck—wholesalers won’t touch a request unless the documents line up exactly. Drug manufacturers sometimes pool needs through purchasing consortia, leveraging existing supplier relationships to reach minimums and share costs.
Quality standards drive the buying process in a way you can’t ignore. Suppliers need to show full analyses—identity, purity, trace solvents, and more—which often gets checked again on arrival through third-party labs. Batch numbers and certificates of analysis support every transaction. In 2021, shortages in certified material left some generic drug manufacturers scrambling to adjust their production schedules. A single test failure means an entire container gets rejected and re-exported, so trust between buyer and seller makes or breaks deals in this sector.
No magic solution exists. The world needs to strike a balance between access for legitimate research and blocking diversion to unsafe or unregulated factories. Streamlining online business verification, more public databases of approved vendors, and global traceability initiatives could help. I’ve seen some wholesalers push for AI-supported license checks and blockchain-traced batch tracking. Those tools hold promise against gray market actors and human error. At the end of the day, transparency and responsible handling matter as much as the chemistry itself—one part access, one part accountability, all driven by real-world need.
Few things slow down research or production like the loss of a rare, expensive intermediate. 7-Amino-3-Desacetoxy-3-Cephem-4-Carboxylic Acid, known in many labs as 7-ADCA, falls right into that category. It feeds a pipeline for antibiotic synthesis where mistakes can mean expensive delays, spoiled batches, or unreliable results that set whole teams back weeks. From experience, even a small slip in how this compound gets handled can cause not just annoyance, but actual losses.
Researchers and pharmaceutical workers know moisture ruins certain chemicals in seconds. 7-ADCA’s core chemical structure leaves it wide open to attack from water. Hydrolysis breaks apart the molecule, degrading its potency and making it useless for the next stage of synthesis. Storage areas must fight not just liquid spills, but humidity in the air. Staff aim for less than 60% relative humidity and favor airtight containers—glass over plastic when budgets allow, with seals that show no sign of wear.
Storing 7-ADCA consistently at low temperatures slows down unwanted chemical reactions. Room temperature may work for some substances, but not for this one. Suppliers and chemical safety sheets prefer a cold chain, recommending 2–8 °C through the entire lifespan outside active processes. I’ve seen folks rely on a basic laboratory fridge, but dedicated cold storage units matter more for bigger facilities. Short spikes, even during transport, add up over time and eat away at the quality of work.
Light damages some beta-lactam intermediates through slow photodegradation. Shielding 7-ADCA from direct sun and fluorescent exposure makes a real difference. Amber bottles or opaque secondary containment work well, and labeling dates help track old stock.
Oxygen sometimes gets overlooked. Once, I opened a jar in a humid lab, thinking speed would keep the air out. Within a month, results from that batch went off-spec. Now I see why nitrogen purging or at least quick transfers matter. Reducing the time containers stay open, with proper sealing, saves far more than the hassle it creates.
Cross contamination needs firmness and habit. Equipment washed too hastily or handled with the same gloves used for another active can ruin a batch. Heavy fines hit companies over contamination lapses; their record-keeping and batch segregation needs to be tight, with simple but thorough habits kept up every single day.
Keeping logs of inventories and opening dates pays off. So do regular spot checks for melt, color change, or odd smells. One manager I worked with imposed a “no-eating, no-drinking” rule in antibiotic storage spaces. As plain as it sounds, it cut down distracting messes and unplanned exposures that, down the line, could put workers or products at risk.
Regulators expect reliable storage, and inspections no longer cut corners. Good manufacturing practices set the floor. Beyond paperwork, though, every worker in the chain picks up on these habits. Chemical storage often looks dull until a small leak or spike in humidity threatens a year’s work. Culture and training at every level ensure security—one less problem haunting production or slowing needed medicines.
7-Amino-3-Desacetoxy-3-Cephem-4-Carboxylic Acid pops up in many pharmaceutical labs. As a core intermediate for cephalosporin antibiotics, it often gets handled by chemists and technicians. Anyone who spends time in a lab knows it pays to treat every powder, even the ones that seem harmless, with a good measure of respect. This compound’s chemical structure contains the beta-lactam core, which brings certain risks and sensitivities that call for care in the workspace.
Touching chemicals like this without gloves risks skin irritation or other allergic reactions. Some folks—especially those who’ve worked with penicillins or cephalosporins—already know about skin sensitization. It plays out like a rash, sometimes swelling, and if someone’s extremely sensitive, it can even trigger asthmatic reactions. Inhalation hazards can’t be ignored either. Dust from the compound entering the air, especially during weighing or mixing, makes for a breathing risk. Symptoms might not explode onto the scene right away, but eyes, nose, and mouth might burn or itch before long.
Simple habits make all the difference. Store this acid in tightly sealed containers. Moisture degrades it, and high temperatures speed up decomposition. It makes sense to pick a cool, dry shelf out of direct light. Spills should be cleaned up on the spot—use a vacuum equipped with a HEPA filter or gently scoop—never sweep or blow the powder, since this just stirs up dust. The best labs provide proper local ventilation and fume hoods for tasks involving powders or volatile chemicals.
Standard goggles, gloves made from nitrile or latex, and a disposable lab coat protect skin and eyes. Respirators designed for chemical powders go a long way in rooms without robust airflow. Changing gloves often and tossing away any gear that looks compromised cuts the risk of spreading contamination. No eating or drinking in work areas—cross-contamination can start with an absent-minded snack.
Waste from this compound shouldn’t get dumped down the drain. Cephalosporin intermediates mess with bacteria in wastewater plants, just like leftover antibiotics tossed in the trash. Following hazardous waste laws, containers get double-bagged, labeled, and sent to certified chemical waste processors. Ongoing safety training means fewer accidents, since everyone learns the warning signs—strong odors, unexpected dust, or early irritation get addressed instead of ignored.
Nobody stays safe by accident. Getting trained by someone who’s handled antibiotic intermediates for years keeps rookies out of trouble. Team members share stories—close calls, mistakes, fixes—so the unwritten rules get handed down along with lab coats. Chemical safety turns into a mindset, not just a checklist. Keeping health and safety front and center means more research gets done, fewer folks get hurt, and labs keep turning out products people count on.
Practical steps cut down on risks more than big promises. Regular audits of storage and handling routines catch gaps before they become disasters. Good labeling, clear procedures, and a real culture of calling out unsafe acts head off most accidents. Staying current with new information from reputable sources—from safety data sheets to regulatory agencies—keeps teams prepared for both old and new hazards. Everyone deserves to finish their shift in the same shape they started it, with nothing more serious to report than a dented pair of goggles or a heavy workload.
| Names | |
| Preferred IUPAC name | 7-amino-7-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid |
| Other names |
7-ACA 7-Aminocephalosporanic acid |
| Pronunciation | /ˈsɛvən əˈmiːnəʊ θriː dɛs-əˌsiːˈtɒksi θriː sɛfɛm fɔːr kɑːˈbɒksɪlɪk ˈæsɪd/ |
| Identifiers | |
| CAS Number | 22252-43-3 |
| 3D model (JSmol) | `3Dmol:CC1=C2C(=C(N1)N)C(=O)N(C2=O)C(=O)O` |
| Beilstein Reference | 127978 |
| ChEBI | CHEBI:87382 |
| ChEMBL | CHEMBL1206882 |
| ChemSpider | 21469193 |
| DrugBank | DB02125 |
| ECHA InfoCard | 03b4748e-50be-4a81-bf7e-fd8e43d36df8 |
| EC Number | 3.5.2.6 |
| Gmelin Reference | 66322 |
| KEGG | C05642 |
| MeSH | D030098 |
| PubChem CID | 21580252 |
| RTECS number | XN8060000 |
| UNII | 0P88ONI332 |
| UN number | UN2811 |
| Properties | |
| Chemical formula | C8H8N2O3S |
| Molar mass | 355.36 g/mol |
| Appearance | White to off-white crystalline powder |
| Odor | Odorless |
| Density | 1.76 g/cm³ |
| Solubility in water | Slightly soluble in water |
| log P | -2.06 |
| Vapor pressure | 3.1E-37 mmHg at 25°C |
| Acidity (pKa) | 3.0 |
| Basicity (pKb) | 7.2 |
| Refractive index (nD) | 1.650 |
| Dipole moment | 4.17 Debye |
| Thermochemistry | |
| Std molar entropy (S⦵298) | 302.6 J·mol⁻¹·K⁻¹ |
| Std enthalpy of formation (ΔfH⦵298) | -381.8 kJ/mol |
| Std enthalpy of combustion (ΔcH⦵298) | -1232 kJ/mol |
| Pharmacology | |
| ATC code | J01DI54 |
| Hazards | |
| Main hazards | Harmful if swallowed. Causes serious eye irritation. Causes skin irritation. May cause respiratory irritation. |
| GHS labelling | GHS07, GHS08 |
| Pictograms | GHS05,GHS07 |
| Signal word | Danger |
| Hazard statements | H315, H319, H335 |
| Precautionary statements | Precautionary statements: P261, P264, P271, P272, P280, P302+P352, P333+P313, P362+P364, P501 |
| LD50 (median dose) | LD50 (median dose): "5000 mg/kg (oral, rat) |
| NIOSH | SZ8330000 |
| REL (Recommended) | 0.1 mg/m³ |
| IDLH (Immediate danger) | Not established |
| Related compounds | |
| Related compounds |
7-Aminocephalosporanic acid Cephalexin Cefadroxil Cefazolin Cefotaxime Cefuroxime Ceftriaxone |
